semaglutide type 1 diabetes randomized trial 2024 Effectiveness of and Tirzepatide in Overweight and Obese Adults with Subcutaneous weekly semaglutide with automated

10.1016/j.ijantimicag.2021.106372 Int J Antimicrob Agents

FDAs primary concern is marketing that blurs the distinction between compounded products and FDAapproved drugsrather than the lawful act of compounding under FDCA 503A or 503B

Contraindications: Do not use in cases of known hypersensitivity to the active ingredient

I just started Reta last week, one member posted

The CORE Diabetes Model: projecting long-term clinical outcomes, costs and costeffectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making

That is a real domain of legitimacy, but it is not evidence for injected whole-body regeneration